|
KMID : 0383820090660020104
|
|
Tuberculosis and Respiratory Diseases
2009 Volume.66 No. 2 p.104 ~ p.109
|
|
|
Efficacy of Darbepoetin alfa in Anemia Developed during
|
|
Ban Hee-Jung
Oh In-Jae
Kim Kyu-Sik
Kim Yu-Il
Lim Sung-Chul
Kim Young-Chul
Ju Jin-Young
Chi Su-Young
Kwon Yong-Soo
Park Cheol-Kyu
Kim Eun-Young
Kim Yoon-Hee
|
|
|
Abstract
|
|
|
Background: Anemia is quite common in lung cancer patients and known to decrease the quality of life.
Darbepoetin alfa is an erythropoiesis-stimulating protein approved for administration to cancer patients. This study
examined the efficacy and safety of darbepoetin alfa in lung cancer patients with a hemoglobin concentration
＜10 g/dl during chemotherapy.
Methods: Lung cancer patients (n=178) received darbepoetin alfa at doses of 1.91 μg/kg per week until the
hemoglobin concentration increased to ＞10 g/dl. The efficacy and safety were measured by comparing the
hemoglobin concentration and assessing the adverse events.
Results: After chemotherapy, the hemoglobin concentration decreased to 9.03±0.64 g/dl. With the darbepoetin
alfa treatment, the hemoglobin concentration increased to 10.09±1.17 g/dl after 4 weeks reaching a peak
hemoglobin concentration of 10.45±1.18 g/dl. The changes in hemoglobin after 4 and 8 weeks with treatment
were 1.08±1.24 g/dl and 1.38±1.59 g/dl (p＜0.01). At least a 1 g/dl or more increase in hemoglobin was observed
in 62.4% of patients. There were no serious adverse effects except for some mild reactions.
Conclusion: Darbepoetin alfa administered to lung cancer patients appears to be an effective, well-tolerated
treatment for chemotherapy induced anemia.
|
|
|
KEYWORD
|
|
|
Darbepoetin alfa, Anemia, Lung cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|